Format

Send to

Choose Destination
See comment in PubMed Commons below
Pulm Pharmacol Ther. 2013 Apr;26(2):212-7. doi: 10.1016/j.pupt.2012.10.008. Epub 2012 Nov 7.

Statins, systemic inflammation and risk of death in COPD: the Rotterdam study.

Author information

1
Department of Respiratory Medicine, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. lies.lahousse@ugent.be

Abstract

BACKGROUND:

Studies suggest that statins decrease mortality in COPD patients but it is unknown which patients might benefit most.

OBJECTIVES:

We investigated whether statins were associated with reduced mortality in COPD patients and whether effects differed according to baseline high-sensitivity C-reactive protein (hsCRP) concentration, a marker of systemic inflammation.

METHODS:

This nested case-control study was part of the Rotterdam Study, a prospective population-based cohort study among 7983 subjects ≥ 55 years. Using automated pharmacy records, we evaluated statin use of 363 cases (COPD patients who died during follow-up of 17 years) with 2345 age and sex matched controls (COPD patients who survived the follow-up period of the index case).

RESULTS:

Compared to never use, long-term statin use (>2 years) was associated with a 39% decreased risk of death in COPD patients. Stratified according to the level of systemic inflammation, long-term statin use was associated with a 78% reduced mortality if hsCRP level > 3 mg/L, versus a non significant 21% reduced mortality if hsCRP level ≤ 3 mg/L.

CONCLUSIONS:

Statin use is associated with a beneficial effect on all-cause mortality in COPD, depending on the baseline level of systemic inflammation.

PMID:
23142156
DOI:
10.1016/j.pupt.2012.10.008
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center